In 2002 Kratz and co-workers investigated antitumor efficacy and toxicity of four albumin-binding Dox prodrugs, demonstrating that especially the (6-maleimidocaproyl)hydrazone derivative of Dox (Aldoxorubicin (Aldox), formerly known as INNO-206, CytRx Corporation), selectively bound to the cysteine-34 position of endogenous albumin, was superior to the parent molecule Dox in a murine renal cell carcinoma model and in breast carcinoma xenograft models [3]. Here, ALB is linked to breast carcinoma.